JTL
CTMX icon

Jupiter Topco LLC’s CytomX Therapeutics CTMX Stock Holding History

Jupiter Topco LLC’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
+46,700
New +$178K ﹤0.01% 2425

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EC
Elmind Capital New York $398M AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Jupiter Topco LLC's CTMX Position: Q2 2026 in Review

Jupiter Topco LLC opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 46,700 shares worth $175K. The stake represents ﹤0.01% of the portfolio and ranks #2425 among its holdings.

161 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Jupiter Topco LLC held 46,700 shares of CytomX Therapeutics worth $175K as of Q2 2026.
  • CytomX Therapeutics was a new Jupiter Topco LLC position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Jupiter Topco LLC's portfolio in Q2 2026, its #2425 holding.
  • 161 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Jupiter Topco LLC's 13F filing for Q2 2026, filed 14 Aug 2026.